

STEERING COMMITTEE

Center for Science in the
Public Interest

Environmental Defense

Food Animal Concerns
Trust

Global Resource Action
Center for the Environment

Humane Society of the
United States

Institute for Agriculture
and Trade Policy

National Catholic Rural Life
Conference

Natural Resources Defense
Council

Physicians for Social
Responsibility

Safe Tables Our Priority
(S.T.O.P.)

Sierra Club

Union of Concerned
Scientists

Waterkeeper Alliance

April 27, 2006

Public Information and Records Integrity Branch (PIRIB) (7502C)
Office of Pesticide Programs (OPP)
Environmental Protection Agency
1200 Pennsylvania Ave., NW.
Washington, DC 20460-0001

Attention: Docket ID number EPA-HQ-OPP-2006-0234

Dear Sir or Madam,

On behalf of Keep Antibiotics Working (KAW), a coalition of health, consumer, agricultural, environmental, humane, and other advocacy groups, I write to urge you to deny the request from the Michigan Department of Agriculture for a specific exemption to use the pesticide gentamicin to control streptomycin-resistance fire blight.

KAW believes that the pesticide use of this highly important medical drug presents an avoidable and significant risk to public health. Indeed, we question whether highly important human drugs like gentamicin should ever be broadcast sprayed as pesticides, due to concerns about their contribution to antimicrobial resistance, and resultant threats to human health.

Gentamicin is highly important for the treatment of serious infections in humans.

When an application for the registration of gentamicin as a pesticide was made in 1994, KAW member group the Union of Concerned Scientists (UCS) opposed the registration on public health grounds (KAW Attachment 2: UCS Letter), because of the risk of antimicrobial resistance. At the same time, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the American Society for Microbiology all opposed the registration on human health grounds as well (reported in McManus, 2002). CDC (KAW Attachment 3: CDC Letter) noted at that time that gentamicin continues to be an important drug for treating sepsis in adults and is particularly important for treating neonatal sepsis. CDC also noted that the environmental use of this pesticide would increase the risk of resistance developing, because bacteria in sprayed orchards would be exposed to a concentration gradient of the pesticide. The concerns expressed by these commentators on the application for gentamicin registration are still relevant.

The World Health Organization designated gentamicin a critically important drug for human medicine (WHO, 2005). FDA considers gentamicin and other aminoglycosides as highly important for human medicine, because of their importance in treating enterococcal endocarditis and other serious infections (FDA, 2003).

Gentamicin is particularly important for the treatment of neonatal sepsis. While cephalosporins have increasingly been used as an alternative, recent research has shown that this may be misguided in the absence of specific information on gentamicin resistance. In a large study examining the outcomes of patients in a neonatal intensive care unit Clark et al. (2006) found lower mortality in patients that received gentamicin concurrently with ampicillin than in patients receiving cefotaxime with ampicillin.

Despite problems with nephrotoxicity and ototoxicity, Aminoglycosides have distinct properties that make them useful including “concentration-dependent bactericidal activity, postantibiotic effect, relatively predictable pharmacokinetics, and synergism with other antibiotics” (Vakulenko and Mobashery, 2003).

Aminoglycosides are important for treating a variety of serious illnesses. They are used to treat serious infections caused by aerobic gram-negative infections including Enterobacteriaceae and *Pseudomonas aeruginosa* usually in combination with other drugs (Vakulenko and Mobashery, 2003). *Escherichia coli*, a member of the Enterobacteriaceae family, has been detected on apples while apple products have been associated with illness caused by *E. coli* (Lang et al, 1999). *Pseudomonas aeruginosa* is a common cause of serious nosocomial infections. While the connection between resistant fruit pathogens and nosocomial infection may seem remote, there is evidence that genes conferring high level beta-lactam resistance in hospital *Pseudomonas* infections originated in the fruit pathogen *Xanthomonas citri* (Jones, 2005).

Aminoglycosides are also important for treating enterococcal infections including enterococcal meningitis (Tunkel et al., 2004) and infective endocarditis (Baddour et al., 2005). Enterococci are readily found on apples even after washing (Lang et al., 1999). KAW believes the use of gentamicin as a pesticide for fruit in response to streptomycin resistance in the fruit pathogen is particularly misguided because gentamicin is used to treat human enterococcal infections that have become resistant to streptomycin (Baddour et al., 2005). Enterococci resistant to both streptomycin and gentamicin would be more difficult to treat than bacteria resistant to either one singly.

Gentamicin and streptomycin are the treatments of choice for tularemia (Maurin and Raoult, 2001). Because there is not cross resistance between streptomycin and gentamicin, one may be substituted for the other when resistance is present. Using gentamicin in an orchard where streptomycin resistance is already high may lead to tularemia that is difficult to treat. There are alternatives to aminoglycosides for tularemia treatment, but these have higher relapse rates (Hassoun et al., 2006). Tularemia can be found everywhere in the state of Michigan and infects animals common in orchards such as rabbits (Michigan DNR, 2006). The exposure of infected animals to low levels of gentamicin, which is likely when the drug is sprayed on fruit

trees, will increase the risk of gentamicin resistance in the bacteria that cause tularemia. The likelihood that this will occur is increased because spraying occurs in the spring, the same period when the disease is most prevalent.

The risk that gentamicin when used as a pesticide will create a public health hazard through the selection of resistant bacteria has not been evaluated by the EPA.

KAW believes that information on the public health risks of the pesticide use of gentamicin was sufficient to deny the application for registration and is sufficient to deny this request for a specific exemption. If the EPA does not believe that this information is sufficient to deny the request for an emergency exemption, then EPA should complete an assessment of the risk before approving the exemption. EPA recently published and asked for comments on assessments of the risks of antimicrobial resistance from the pesticide use of streptomycin (EPA Docket ID Number EPA-HQ-OPP-2005-0493) and oxytetracycline (EPA Docket ID Number EPA-HQ-OPP-2005-0492). The EPA modeled these risk assessments on the FDA's Guidance for Industry 152. Both found either a medium or high risk for creating adverse human health impacts. This approach, if applied to the risk assessment of the human health hazard from the pesticide use of gentamicin, would likely lead to the same result. Resistance to gentamicin like other aminoglycosides is commonly carried on mobile elements that are readily transferred between bacteria. Although there are no reports of gentamicin resistance in fruit pathogens in Michigan, this says nothing about the risk of using this highly important antibiotic as a pesticide; rather, it only reflects the absence of use of this unregistered pesticide. Without a thorough assessment of the risks of antimicrobial resistance developing from this proposed emergency use of gentamicin, it is inappropriate to accept the request.

Because streptomycin-resistant fire blight occurs every year in Michigan, it is inappropriate to consider this situation an emergency.

According to the Federal Code (40CFR166.3), an emergency condition is a "non-routine situation." Streptomycin resistance in the fire blight pathogen is a routine condition in Michigan and should not be considered an emergency. This is particularly true given that the claimed emergency occurred because fruit growers decided to grow susceptible fruit varieties on susceptible root stock planted at higher densities than what has been traditionally followed in Michigan (Longstroth, 2002). An alternative approach would be to plant resistant varieties at healthy stocking densities and market the fruit as antibiotic free.

Conclusion:

KAW urges EPA to deny the request for a specific exemption by the Michigan Department of Agriculture to use the unregistered pesticide gentamicin to control streptomycin-resistant fire blight. KAW believes that the pesticide use of gentamicin is likely to compromise the usefulness of this highly important medicine in treating serious human illness.

Sincerely,

Steven Roach
Food Safety Program Manager
Food Animal Concerns Trust
P.O. Box 14599
Chicago, IL 60614

Larissa McKenna, MS, MPH
Coordinator
Keep Antibiotics Working Coalition
P.O. Box 14590
Chicago, IL 60614

References:

Baddour et al., 2005. Infective Endocarditis. *Circulation* 111:e394-e433.

FDA, 2003. Guidance for Industry #152: Evaluating the Safety of Antibacterial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern.

Hassoun et al., 2006. Tularemia and Once Daily Gentamicin. *Antimicrobial Agents and Chemotherapy* 50(2) :824.

Jones, 2005. Emerging Antimicrobial Resistance Trends in Human Medicine: A Global Review of Selected Surveillance Programs. 2005 Annual Conference on Antimicrobial Resistance, June 27-29, Bethesda, Maryland.

Lang et al, 1999. Verifying Apple cider Plant Sanitation and Hazard Analysis Critical Control Point Programs: Choice of Indicator Bacteria and Testing Methods. *Journal of Food Protection* 62:887-893.

Longstroth, 2002. The 2000 Fire blight Epidemic in Southwest Michigan. Accessed online April 12, 2006. <http://www.canr.msu.edu/vanburen/fb2000.htm>

Maurin and Raoult, 2001. Use of Aminoglycosides in Treatment of Infections Due to Intracellular Bacteria. *Antimicrobial Agents and Chemotherapy* 45(11): 2977-2986.

McManus, 2002. Antibiotic Use in Plant Agriculture. *Annual Review of Phytopathology* 40:443-65.

Michigan DNR, 2006. Tularemia. Available at: http://www.michigan.gov/dnr/0,1607,7-153-10370_12150_12220-27293--,00.html. Accessed March 25, 2006.

Tunkel et al., 2005. Practice Guidelines for the Management of Bacterial Meningitis. *Clinical Infectious Diseases* 39:1267-1284.

Vakulenko and Mobashery, 2003. Versatility of Aminoglycosides and Prospects for Their Future.

WHO, 2005. Critically Important Antibacterial Agents for Human Medicine for Risk Management Strategies of Non-Human Use: report of a WHO working group consultation, 15-18 February 2005, Canberra, Australia. Available on line at: http://www.who.int/foodborne_disease/resistance/amr_feb2005.pdf